Studies open for recruitment



Liver Studies


1. Protocol: 747-303 (PI: Dr Mark McCullen)
Short Title: The REGENERATE Study.

Protocol Title: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis.

Lay Title: Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Click here for more information


2. Protocol: 3152-301-002 (PI: Dr Darrell Crawford)
Short Title: The AURORA Study.

Protocol Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

Lay Title: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH (AURORA)
3. Protocol: LJ401-HH01 (PI: Dr Darrell Crawford)

Protocol Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study with LJPC-401 for the Treatment of Iron Overload in Adult Patients with Hereditary Hemochromatosis

Lay Title: A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Click here for more information


4. Protocol: 747-304 (PI: Dr Mark McCullen)
Short Title: The REVERSE Study.

Protocol Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Lay Title: Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE)
1. Protocol: MK-3475-022. KEYNOTE-022 (PI: Dr Victoria Atkinson)
Short Title: The KEYNOTE-022  study
Protocol Title: A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma.

Lay Title: A study to investigate MK-3475 (pembrolizamab) in combination with trametinib and dabrafenib in patients with advanced melanoma.


2. Protocol: Protocol: CA224-020 (PART D) (PI: Dr Victoria Atkinson)
Protocol Title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced  Solid Tumors

Lay Title: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid  (Part D: melanoma that HAVE previously been treated with immunotherapy)


3. Protocol: CK-101-101 (PI: Dr Ken O’Byrne)
Protocol Title: A Phase I/II, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients With Advanced Solid Tumors

Lay Title: Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors


4. Protocol: INCAGN 1876-201 (PI: Dr Warren Joubert)
Protocol Title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Lay Title: A Clinical trial with the purpose to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.


5. Protocol: 2125-MEL-301(PI: Dr Victoria Atkinson)
Short Title: The ILLUMINATE 301 study

Protocol Title: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

Lay Title: A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma

Click here for more information


6. Protocol: CA224-047 (PI: Dr Victoria Atkinson)

Protocol Title: A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma

Lay Title: A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Click here for more information


7. Protocol: I8X-MC-JECA (Part B & C) (PI: Dr Victoria Atkinson)
Protocol Title: A Phase 1 Study of LY3200882 in Patients with Solid Tumors

Lay Title: A Phase 1 Study of LY3200882 in Patients with Solid Tumors

Click here for more information


8. Protocol: (D081SC00001) (PI: Dr Pretoria Bilinski)
Short Title: The PROpel study

Protocol Title: A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)

Lay Title: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Click here for more information


9. Protocol: (MK3475-495) (PI: Dr Ken O’Byrne)
Short Title: KEYNOTE-495; KeyImPaCT

Protocol Title: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Lay Title: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495)

Click here for more information



Respiratory  Studies


1. Protocol: INS1007-201 (PI: Dr Rachel Thomson)
Short Title: The WILLOW Study

Protocol Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis

Lay Title: Assessment of INS1007 in Subjects With Non-Cystic Fibrosis Bronchiectasis (WILLOW)

Click here for more information


2. Protocol: Z7224L01 (PI: Dr Rachel Thomson)
Short Title: The PROMIS I Study

Protocol Title: A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)

Lay Title: Long Term Efficacy and Safety of Inhaled Colistimethate Sodium in Bronchiectasis Subjects With Chronic Pseudomonas Aeruginosa Infection. (PROMIS-I)

Click here for more information


 

 

Resources

View Resources